Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma

Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)

Hendricks H. Whitman, Elliot K Fishman, Kjell Öberg, Joseph M. Wildman, Andrea L. Long

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Catecholamine-secreting metastatic carcinoid should be considered in differential diagnosis of malignant pheochromocytoma. Paroxysmal functioning or hormonally silent gastroenteropancreatic neuroendocrine tumors (GEP NETs) require repeat biochemical measurements and sensitive anatomic and functional imaging studies overlapping those for malignant pheochromocytoma. This report presents clinical, laboratory, and radiologic findings in a patient presenting with heart rate variability; vasoactive headaches reactive to ethanol, tyramine and tryptophan; labile blood pressure; diaphoresis; diarrhea; abdominal pain; unexplained pancreatitis; joint pain; and paroxysmal flushing with pallor. GI studies (including endoscopic ultrasound) and multiple imaging modalities (including 2D CT, MRI with gadolinium, [18]FDG PET/CT, [ 123I]MIBG, and SRS [111In]Octreotide [OctreoScan]) were not diagnostic. 24-h BP, Holter and 30-day cardiac event monitors plus urinary biochemical studies consistently suggested catecholamine-synthesizing NET. NIH plasma metanephrines studies and [6]-[18F]Fluorodopamine PET ruled out malignant pheochromocytoma (pheo). Repeated studies showed persistently abnormal GEP NET biomarkers and urinary catecholamines. Capsule endoscopy revealed suspicious submucosal lesions throughout the small intestine. Dual-phase 64-slice multidetector computed tomography (MDCT) with 3D volumetric reconstruction of the abdomen and pelvis revealed multiple diffuse liver metastases and three extrahepatic lesions consistent with metastatic carcinoid. In combination, intensive biochemical testing repeated over time, dual-phase 64-slice MDCT with 3D image reconstruction and volume-rendering (VR) technique, and advanced radionuclide imaging are required to detect NETs' sporadic or paroxysmal functioning, rule out extra-adrenal pheochromocytoma, and localize and characterize metastatic carcinoid. If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages59-78
Number of pages20
Volume1073
DOIs
StatePublished - Aug 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1073
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Clinical laboratories
Neuroendocrine Tumors
Carcinoid Tumor
Medical imaging
Pheochromocytoma
Catecholamines
Tumors
Multidetector computed tomography
Differential Diagnosis
Imaging techniques
Multidetector Computed Tomography
Metanephrine
3-Iodobenzylguanidine
Volume rendering
Tyramine
Endoscopy
Blood pressure
Gadolinium
Capsule Endoscopy
Pallor

Keywords

  • Carcinoid
  • Catecholamines
  • Imaging
  • Multidetector CT (MDCT)
  • Pheochromocytoma
  • Tumor markers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Whitman, H. H., Fishman, E. K., Öberg, K., Wildman, J. M., & Long, A. L. (2006). Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). In Annals of the New York Academy of Sciences (Vol. 1073, pp. 59-78). (Annals of the New York Academy of Sciences; Vol. 1073). https://doi.org/10.1196/annals.1353.007

Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma : Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). / Whitman, Hendricks H.; Fishman, Elliot K; Öberg, Kjell; Wildman, Joseph M.; Long, Andrea L.

Annals of the New York Academy of Sciences. Vol. 1073 2006. p. 59-78 (Annals of the New York Academy of Sciences; Vol. 1073).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Whitman, HH, Fishman, EK, Öberg, K, Wildman, JM & Long, AL 2006, Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). in Annals of the New York Academy of Sciences. vol. 1073, Annals of the New York Academy of Sciences, vol. 1073, pp. 59-78. https://doi.org/10.1196/annals.1353.007
Whitman HH, Fishman EK, Öberg K, Wildman JM, Long AL. Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). In Annals of the New York Academy of Sciences. Vol. 1073. 2006. p. 59-78. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1353.007
Whitman, Hendricks H. ; Fishman, Elliot K ; Öberg, Kjell ; Wildman, Joseph M. ; Long, Andrea L. / Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma : Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). Annals of the New York Academy of Sciences. Vol. 1073 2006. pp. 59-78 (Annals of the New York Academy of Sciences).
@inproceedings{1676a5ac8f3346ae83a739fffaebd23d,
title = "Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)",
abstract = "Catecholamine-secreting metastatic carcinoid should be considered in differential diagnosis of malignant pheochromocytoma. Paroxysmal functioning or hormonally silent gastroenteropancreatic neuroendocrine tumors (GEP NETs) require repeat biochemical measurements and sensitive anatomic and functional imaging studies overlapping those for malignant pheochromocytoma. This report presents clinical, laboratory, and radiologic findings in a patient presenting with heart rate variability; vasoactive headaches reactive to ethanol, tyramine and tryptophan; labile blood pressure; diaphoresis; diarrhea; abdominal pain; unexplained pancreatitis; joint pain; and paroxysmal flushing with pallor. GI studies (including endoscopic ultrasound) and multiple imaging modalities (including 2D CT, MRI with gadolinium, [18]FDG PET/CT, [ 123I]MIBG, and SRS [111In]Octreotide [OctreoScan]) were not diagnostic. 24-h BP, Holter and 30-day cardiac event monitors plus urinary biochemical studies consistently suggested catecholamine-synthesizing NET. NIH plasma metanephrines studies and [6]-[18F]Fluorodopamine PET ruled out malignant pheochromocytoma (pheo). Repeated studies showed persistently abnormal GEP NET biomarkers and urinary catecholamines. Capsule endoscopy revealed suspicious submucosal lesions throughout the small intestine. Dual-phase 64-slice multidetector computed tomography (MDCT) with 3D volumetric reconstruction of the abdomen and pelvis revealed multiple diffuse liver metastases and three extrahepatic lesions consistent with metastatic carcinoid. In combination, intensive biochemical testing repeated over time, dual-phase 64-slice MDCT with 3D image reconstruction and volume-rendering (VR) technique, and advanced radionuclide imaging are required to detect NETs' sporadic or paroxysmal functioning, rule out extra-adrenal pheochromocytoma, and localize and characterize metastatic carcinoid. If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis.",
keywords = "Carcinoid, Catecholamines, Imaging, Multidetector CT (MDCT), Pheochromocytoma, Tumor markers",
author = "Whitman, {Hendricks H.} and Fishman, {Elliot K} and Kjell {\"O}berg and Wildman, {Joseph M.} and Long, {Andrea L.}",
year = "2006",
month = "8",
doi = "10.1196/annals.1353.007",
language = "English (US)",
isbn = "1573315974",
volume = "1073",
series = "Annals of the New York Academy of Sciences",
pages = "59--78",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma

T2 - Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)

AU - Whitman, Hendricks H.

AU - Fishman, Elliot K

AU - Öberg, Kjell

AU - Wildman, Joseph M.

AU - Long, Andrea L.

PY - 2006/8

Y1 - 2006/8

N2 - Catecholamine-secreting metastatic carcinoid should be considered in differential diagnosis of malignant pheochromocytoma. Paroxysmal functioning or hormonally silent gastroenteropancreatic neuroendocrine tumors (GEP NETs) require repeat biochemical measurements and sensitive anatomic and functional imaging studies overlapping those for malignant pheochromocytoma. This report presents clinical, laboratory, and radiologic findings in a patient presenting with heart rate variability; vasoactive headaches reactive to ethanol, tyramine and tryptophan; labile blood pressure; diaphoresis; diarrhea; abdominal pain; unexplained pancreatitis; joint pain; and paroxysmal flushing with pallor. GI studies (including endoscopic ultrasound) and multiple imaging modalities (including 2D CT, MRI with gadolinium, [18]FDG PET/CT, [ 123I]MIBG, and SRS [111In]Octreotide [OctreoScan]) were not diagnostic. 24-h BP, Holter and 30-day cardiac event monitors plus urinary biochemical studies consistently suggested catecholamine-synthesizing NET. NIH plasma metanephrines studies and [6]-[18F]Fluorodopamine PET ruled out malignant pheochromocytoma (pheo). Repeated studies showed persistently abnormal GEP NET biomarkers and urinary catecholamines. Capsule endoscopy revealed suspicious submucosal lesions throughout the small intestine. Dual-phase 64-slice multidetector computed tomography (MDCT) with 3D volumetric reconstruction of the abdomen and pelvis revealed multiple diffuse liver metastases and three extrahepatic lesions consistent with metastatic carcinoid. In combination, intensive biochemical testing repeated over time, dual-phase 64-slice MDCT with 3D image reconstruction and volume-rendering (VR) technique, and advanced radionuclide imaging are required to detect NETs' sporadic or paroxysmal functioning, rule out extra-adrenal pheochromocytoma, and localize and characterize metastatic carcinoid. If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis.

AB - Catecholamine-secreting metastatic carcinoid should be considered in differential diagnosis of malignant pheochromocytoma. Paroxysmal functioning or hormonally silent gastroenteropancreatic neuroendocrine tumors (GEP NETs) require repeat biochemical measurements and sensitive anatomic and functional imaging studies overlapping those for malignant pheochromocytoma. This report presents clinical, laboratory, and radiologic findings in a patient presenting with heart rate variability; vasoactive headaches reactive to ethanol, tyramine and tryptophan; labile blood pressure; diaphoresis; diarrhea; abdominal pain; unexplained pancreatitis; joint pain; and paroxysmal flushing with pallor. GI studies (including endoscopic ultrasound) and multiple imaging modalities (including 2D CT, MRI with gadolinium, [18]FDG PET/CT, [ 123I]MIBG, and SRS [111In]Octreotide [OctreoScan]) were not diagnostic. 24-h BP, Holter and 30-day cardiac event monitors plus urinary biochemical studies consistently suggested catecholamine-synthesizing NET. NIH plasma metanephrines studies and [6]-[18F]Fluorodopamine PET ruled out malignant pheochromocytoma (pheo). Repeated studies showed persistently abnormal GEP NET biomarkers and urinary catecholamines. Capsule endoscopy revealed suspicious submucosal lesions throughout the small intestine. Dual-phase 64-slice multidetector computed tomography (MDCT) with 3D volumetric reconstruction of the abdomen and pelvis revealed multiple diffuse liver metastases and three extrahepatic lesions consistent with metastatic carcinoid. In combination, intensive biochemical testing repeated over time, dual-phase 64-slice MDCT with 3D image reconstruction and volume-rendering (VR) technique, and advanced radionuclide imaging are required to detect NETs' sporadic or paroxysmal functioning, rule out extra-adrenal pheochromocytoma, and localize and characterize metastatic carcinoid. If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis.

KW - Carcinoid

KW - Catecholamines

KW - Imaging

KW - Multidetector CT (MDCT)

KW - Pheochromocytoma

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=33845479732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845479732&partnerID=8YFLogxK

U2 - 10.1196/annals.1353.007

DO - 10.1196/annals.1353.007

M3 - Conference contribution

SN - 1573315974

SN - 9781573315975

VL - 1073

T3 - Annals of the New York Academy of Sciences

SP - 59

EP - 78

BT - Annals of the New York Academy of Sciences

ER -